In the previous installment of Scrip Asks…What Does 2023 Hold For Biopharma? , we asked what technological advance would have the biggest impact on biopharma in 2023. Artificial intelligence was a fe
The first half of 2022 saw the NASDAQ Biotechnology Index lose a quarter of its value. Despite a tentative recovery since then, the IPO window is barely ajar and valuations remain well below the highs